FIELD: medicine.
SUBSTANCE: invention relates to clinical laboratory diagnostics and can be used for screening test for determination of anticoagulant potential of blood plasma for diagnostics of pre-thrombotic conditions. Essence of the test consists in recalcification of whole blood plasma with calcium chloride and registration of coagulation on a photometer for enzyme immunoassay. Coagulation of whole plasma during incubation for 30 min at 37 °C testifies to reduced anticoagulant potential of blood plasma and threat of thrombosis in viral infection or in inflammatory conditions of a person, as well as in post-covid syndrome.
EFFECT: introduction of the offered test for determination of anticoagulant potential of blood plasma will allow to start prevention of thromboses, strokes and infarctions in time at the stage before cardiovascular accidents.
1 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCREENING-TEST OF DETERMINING COAGULATION CONTACT WAY (STOKPK) | 2017 |
|
RU2660706C1 |
| METHOD FOR DETERMINING ACTIVITY OF ALTERNATIVE COMPLEMENT PATHWAY FOR PREDICTION OF PRE-THROMBOTIC CONDITIONS | 2024 |
|
RU2836056C1 |
| METHOD FOR EVALUATING PLASMA HAEMOSTASIS | 2023 |
|
RU2816538C1 |
| DETERMINING THE ACTIVITY OF THE CLASSICAL PATHWAY OF THE COMPLEMENT SYSTEM IN A FIBRINOGEN COAGULATION TEST | 2019 |
|
RU2707568C1 |
| METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF ANTITHROMBIN III IN BLOOD PLASMA | 2021 |
|
RU2772195C1 |
| METHOD FOR DETERMINING FIBRINOGEN AND FUNCTIONALITY EVALUATION THEREOF | 2020 |
|
RU2732388C1 |
| METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
| METHOD FOR ASSESSING STATE OF HEMOSTASIS | 2023 |
|
RU2817000C1 |
| METHOD FOR PREDICTION OF RISK OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN SEVERE BURN INJURY | 2020 |
|
RU2737277C1 |
| SOLUTION FOR CORRECTION OF PRIMARY HOMEOSTASIS DISORDER WITH PLASMA-SUBSTITUTING SOLUTIONS OF NOVEL COMPOSITION | 2005 |
|
RU2300385C1 |
